Skip to content

Using 32 - Gauge Needles With Lengths of 5 mm and 8 mm on Pain Post-injection, Leak and Blood Glucose

The Effect of Using 32 - Gauge Needles With Lengths of 5 mm and 8 mm on Pain Post-injection, Leak and Blood Glucose Control in Type - II Diabetic Patients in Baqiyatollah Hospital and Clinic, Tehran, 2019 -2020

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04460092
Enrollment
100
Registered
2020-07-07
Start date
2020-05-25
Completion date
2020-09-25
Last updated
2020-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Diabetes Mellitus, Type 2, Blood Glucose, Pain, leakage, insulin injections

Brief summary

This is a Clinical crossover trial study. In this study, 100 patients with type II diabetes will be selected based on entry and exit criteria, then randomly divided into two equal groups (group A and group B).In the first three days of the first week of hospitalization, in group A insulin injection with a 90-degree angle and using Nidel 32-Gauge with a length of 5 mm, and in the other group insulin injection with a 90-degree angle and using Nidel 32-Gauge with a length of 8 mm will be done. After a one-day break, in another three days, the types of needles used in the two groups are moved together. After a one-day break, in another three days, the types of needles used in the two groups are replaced together. Then the VAS scale will be used to assess post-injection pain; the amount of leakage after the injection will be measured in two ways Yes/No, according to the researcher's observation. And to check the effect of Needles on controlling patients' blood sugar, their blood sugar levels will be measured based on the routine of hospital units.

Detailed description

This is a Clinical crossover trial study. In this study, 100 patients with type II diabetes will be selected based on entry and exit criteria, then randomly divided into two equal groups (group A and group B).In the first three days of the first week of hospitalization, in group A insulin injection with a 90-degree angle and using Nidel 32-Gauge with a length of 5 mm, and in the other group insulin injection with a 90-degree angle and using Nidel 32-Gauge with a length of 8 mm will be done. After a one-day break, in another three days, the types of needles used in the two groups are moved together. After a one-day break, in another three days, the types of needles used in the two groups are replaced together. Then the VAS scale will be used to assess post-injection pain; the amount of leakage after the injection will be measured in two ways Yes/No, according to the researcher's observation. And to check the effect of Needles on controlling patients' blood sugar, their blood sugar levels will be measured based on the routine of hospital units. After entering the data in SPSS20 software, the collected data will be analyzed using descriptive statistics (frequency, percentage, mean, standard deviation) and statistical tests (t-test, chi-square).

Interventions

DEVICE5-mm 32-gauge Insulin needles in the first three days of Intervention

32-gauge needles with a length of 5mm to inject insulin in first three days

DEVICE8-mm 32-gauge Insulin needles in the first three days of Intervention

32-gauge needles with a length of 8mm to inject insulin in first three days

DEVICE5-mm 32-gauge Insulin needles in the last three days of Intervention

32-gauge needles with a length of 5mm to inject insulin in second three days

DEVICE8-mm 32-gauge Insulin needles in the last three days of Intervention

32-gauge needles with a length of 8mm to inject insulin in second three days

Sponsors

Baqiyatallah Medical Sciences University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Having type II diabetes * Use injectable insulin for at least two years * BMI \>18 * Lack of mental illness and mental retardation * Use insulin pen

Exclusion criteria

* Lack of desire to participate in the study * Having a skin problem in the injection site

Design outcomes

Primary

MeasureTime frameDescription
Plasma glucoseUp to 7 daysLaboratory check the Plasma glucose according to the routine of the hospital units
Insulin leakageUp to 7 daysThe rate of insulin leakage after injection is observational
Pain when insulin injectionUp to 7 daysSurvey severity pain when insulin injection by Visual Analogue Scale (VAS). This is a numerical scale that tells the patient the severity of their pain from one to ten. The larger the number, the more pain there is.

Countries

Iran

Contacts

Primary ContactMohammad Sadegh Bagheri Baghdasht
hiasdasd0@gmail.com0098 936 8214509

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026